斯坦福大学转化医学中心主任研究员, HBI Solutions Inc.联合创始人; Principal Investigator,Stanford Transformational Medicine Center,Co-founder, HBI Solutions Inc.
Dr. Bruce Ling is a Principal Investigator at Stanford University School of Medicine
and has built a multi-facted laboratory of translational medicine. His wet lab utilizes
muliti-omics based, high throughput, and high content approaches to identify diagnostic
and prognostic utilities for personalized and point of care medicine. His computational lab
currently focuses on novel statistical learning algorithm innovation, large scale scientific
computing and robust experimental design. Prior to that, he was a Research Director at
Tularik Inc responsible for large scale genomics target identification and high throughput
screening of lead compounds. Later Tularik was acquired by Amgen for $1.3 billion and
gave Amgen access to a trove of potential medications for cancer and inflammatory diseases.
Within his tenure at Stanford University, Dr. Ling co-foundered HBI Solutions in 2011 and
focuses on health care analytic solution development, including predictive modeling, and
co-founded Carmenta Bioscience in 2012 to develop diagnostic tools to manage the disease
of preeclampsia in pregnant women.
中国·浙江 湖州市二环东路759号(313000) 浙ICP备10025412号 浙公网安备 33050202000195号 版权所有:党委宣传部